We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Ortho Exhibits High Quality, Accurate and Cost Effective COVID19 Testing Solutions at AACC 2021

By LabMedica International staff writers
Posted on 28 Sep 2021
Print article
Illustration
Illustration

Ortho Clinical Diagnostics (Raritan, NJ, USA) exhibited its range of high quality, accurate and cost effective COVID19 testing solutions at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo held at the Georgia World Congress Center in Atlanta, September 26-30.

Over the span of the four day event, attendees connected with global leaders in clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas of breaking science in laboratory medicine.

Ortho has been at the forefront of developing high quality, accurate, cost effective COVID19 testing solutions that run at high volumes. At AACC 2021, Ortho demonstrated its high-throughput testing solutions for SARS-CoV-2 infection, antibody detection and antigen detection. These included the high-throughput, highly accurate VITROS SARS-CoV-2 antigen test that detects acute infection of SARS-CoV-2. The test delivers fast, high-volume testing for active infection with excellent specificity and sensitivity, making it a viable alternative to PCR testing.

In addition, Ortho highlighted its three qualitative antibody tests, including the VITROS COVID-19 Total and IgG antibody assays that provide highly accurate and reliable detection of SARS-CoV-2 antibodies to help clinicians and researchers understand immune response; and its VITROS Anti-SARS-CoV-2 Total N antibody test that is designed to capture total antibodies to the nucleocapsid protein. Also on display at AACC 2021 was the VITROS Anti-SARS-CoV-2 IgG quantitative test that helps labs to quantify the level of COVID-19 antibodies for patients and individuals in their communities. The VITROS Anti-SARS-CoV-2 IgG quantitative test is the first quantitative test to receive U.S. Food and Drug Administration (FDA) EUA. Ortho also demonstrated its VITROS Performance Dashboard that allows labs to view productivity data from Ortho analyzers including: test volumes, positivity rates, quality and efficiency information to help make more informed decisions for the hospital and community.

Related Links:
Ortho Clinical Diagnostics 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article
ADLM

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: The QIAstat-Dx Respiratory Panel Plus has received U.S. FDA clearance (Photo courtesy of QIAGEN)

New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results

Respiratory tract infections are a major reason for emergency department visits and hospitalizations. According to the CDC, the U.S. sees up to 41 million influenza cases annually, resulting in several... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more